Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo.
Schofield DJ, Irving L, Calo L, Bogstedt A, Rees G, Nuccitelli A, Narwal R, Petrone M, Roberts J, Brown L, Cusdin F, Dosanjh B, Lloyd C, Dobson C, Gurrell I, Fraser G, McFarlane M, Rockenstein E, Spencer B, Masliah E, Spillantini MG, Tan K, Billinton A, Vaughan T, Chessell I, Perkinton MS.
Schofield DJ, et al. Among authors: narwal r.
Neurobiol Dis. 2019 Dec;132:104582. doi: 10.1016/j.nbd.2019.104582. Epub 2019 Aug 21.
Neurobiol Dis. 2019.
PMID: 31445162
Free article.